Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 25,93 € (+109,96%). La mediana è 25,93 € (+109,96%).

Acquista
  13
Mantieni
  0
Vendi
  0

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • MediWound: VALUE study for EscharEx as decisive near-term catalyst

    MediWound presented its bromelain platform at the H.C. Wainwright conference, highlighting NexoBrid revenue potential and the upcoming VALUE phase III study for EscharEx as key drivers. The VALUE study (216 patients) includes an interim analysis at ~65% recruitment; various sample-size adjustments are possible, and topline data are expected about three months after the interim analysis. The company is expanding production capacity, expects European approval in mid‑2027, and points to commercial progress with NexoBrid as well as a BARDA-linked partnership with Vericel. » Altro su de.investing.com


  • MediWound calls extraordinary general meeting for Feb. 19

    MediWound has called an extraordinary general meeting for Feb. 19, 2026, and on Jan. 15, 2026 filed the related notice and a proxy statement with the SEC. Registered shareholders will receive voting materials and a proxy card. The filings give meeting details but do not disclose specific agenda items; the documents refer to existing registration statements on Forms S-8 and F-3. » Altro su de.investing.com


  • MediWound: study shows NexoBrid removes over 90% of traumatic tattoos

    A prospective study at Sheba Medical Center found that MediWound’s enzymatic preparation NexoBrid reduced the pigmented wound surface by an average of 92.5% in 15 patients (96% for abrasion injuries, 84% for blast injuries). The treatment was administered at the bedside under sedation within 24 hours and showed no treatment-related adverse events in early follow-up. MediWound recently raised around $30 million via a direct offering, received approval in Australia and is planning production and capacity expansions; one analyst raised the price target. » Altro su de.investing.com


  • MediWound raises $30 million through registered direct placement

    MediWound sold 1,734,105 ordinary shares at $17.30 per share in a registered direct placement, raising about $30 million. The transaction was led by a U.S. investment fund and other healthcare-focused investors; H.C. Wainwright & Co. served as sole placement agent. Net proceeds are intended to fund precommercial activities for EscharEx, expand manufacturing capacity and general corporate purposes. The company also reported TGA approval of NexoBrid in Australia and new study data on the importance of wound bed preparation. » Altro su de.investing.com


  • MediWound presents growth plan and cites supply bottlenecks for NexoBrid

    MediWound presented its growth strategy at the H.C. Wainwright conference, focusing on the phase-3 study of EscharEx and expansion of production capacity. The company reported supply chain problems with NexoBrid and plans a new manufacturing site in the US as well as an additional facility in Europe to address the shortages. Partnerships with BARDA and the DOD, cash of $33 million and a potential $30 million from warrants support the commercialization plans; a BARDA tender is expected in Q4 2025. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, MediWound ha registrato ricavi pari a 3,15 Mln € e un utile netto di -5,29 Mln €
(EUR) settembre 2026
YoY
Ricavi 3,15 Mln 31,81%
Utile lordo 897,86K 17,60%
Utile netto -5,29 Mln 133,89%
EBITDA -7,2 Mln 287,68%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
159,14 Mln €
Numero di azioni
12,91 Mln
Massimo/minimo a 52 settimane
20,10 € - 10,73 €
Dividendi No
Beta
0,14
Rapporto P/E
-7,45
Rapporto PEG
0,94
Rapporto P/B
5,53
Rapporto P/S
17,48

Profilo aziendale

MediWound Ltd., una società biofarmaceutica, sviluppa, produce e commercializza soluzioni innovative e bioterapeutiche per la riparazione e la rigenerazione dei tessuti. Commercializza NexoBrid, un prodotto biofarmaceutico per la rimozione dell'escara, ovvero tessuto morto o danneggiato, in adulti con ustioni termiche profonde a spessore parziale e totale, destinato ai centri per ustionati e alle unità per ustioni degli ospedali. La società sviluppa inoltre EscharEx, che ha completato le sperimentazioni cliniche di fase II per il debridement di ferite croniche e di altre ferite difficili da guarire; e MW005, che è in fase I/II per il trattamento del carcinoma basocellulare a basso rischio. MediWound Ltd. è stata fondata nel 2000 e ha sede a Yavne, in Israele.

Nome
MediWound
CEO
Ofer Gonen
Sede centrale Yavne, hm
Israele
Sito web
Settore
Beni di prima necessità
Industria
Prodotti per la cura della persona
Quotazione in borsa
20/03/2014
Dipendenti 121

Simboli di borsa

Borsa Simbolo
NASDAQ
MDWD
Frankfurt
M8W.F
🍪

Parqet  usa i cookie. Scopri di più